RITUXAN® (Rituximab) for Non-Hodgkin's Lymphoma (NHL)
Rituxan (Rituximab) INDICATIONS AND USAGE
Non-Hodgkin's Lymphoma (NHL)
Rituxan® is indicated for the treatment of patients with:
- Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
- Previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy
- Non-progressing (including stable disease), low-grade, CD20-positive B-cell NHL, as a single agent, after first-line CVP chemotherapy
- Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens
Rituxan Boxed WARNINGS and Additional Important Safety Information
The most important serious adverse reactions of Rituxan are fatal infusion reactions, tumor lysis syndrome (TLS), severe mucocutaneous reactions, progressive multifocal leukoencephalopathy (PML), hepatitis B reactivation with fulminant hepatitis, other viral infections, cardiovascular events, renal toxicity, and bowel obstruction and perforation. The most common adverse reactions of Rituxan (incidence ≥25%) observed in patients with NHL are infusion reactions, fever, chills, infection, asthenia, and lymphopenia. The most common adverse reactions of Rituxan observed in patients with RA are hypertension, nausea, upper respiratory tract infection, arthralgia, pruritus, and pyrexia.
Attention healthcare provider: Provide Medication Guide to patient prior to Rituxan infusion.
For additional safety information, please see the full prescribing information, including Boxed WARNINGS and Medication Guide.
RITUXAN® (Rituximab) for Rheumatoid Arthritis
Rituxan (Rituximab) INDICATIONS AND USAGE
Rheumatoid Arthritis
Rituxan is a prescription medication used to treat Rheumatoid Arthritis (RA) with another prescription medicine called methotrexate, to reduce the signs and symptoms of moderate to severe active RA in adults, after treatment with at least one other medicine called a Tumor Necrosis Factor (TNF) antagonist has been used and did not work well enough.
People with serious infections should not receive Rituxan.
Rituxan Boxed WARNINGS and Additional Important Safety Information
The most important serious adverse reactions of Rituxan are fatal infusion reactions, tumor lysis syndrome (TLS), severe mucocutaneous reactions, progressive multifocal leukoencephalopathy (PML), hepatitis B reactivation with fulminant hepatitis, other viral infections, cardiovascular events, renal toxicity, and bowel obstruction and perforation. The most common adverse reactions of Rituxan (incidence ≥25%) observed in patients with NHL are infusion reactions, fever, chills, infection, asthenia, and lymphopenia. The most common adverse reactions of Rituxan observed in patients with RA are hypertension, nausea, upper respiratory tract infection, arthralgia, pruritus, and pyrexia.
Attention healthcare provider: Provide Medication Guide to patient prior to Rituxan infusion.
For additional safety information, please see the full prescribing information, including Boxed WARNINGS and Medication Guide.
